REaCT: REthinking Clinical Trials

REaCT-Low Risk HER2

REaCT-Low Risk HER2	Comparing two chemotherapy treatments (TC-Herceptin vs weekly Paclitaxel + Herceptin) for low risk HER2 positive, early stage breast cancer. Principal Investigator(s): Dr. Terry Ng
ClinicalTrials.gov: NCT03705429
In a real-world population with either lower risk breast cancer or increased frailty (older patients, co-morbidities), assessing the relative benefits and toxicity of a chosen chemotherapy regimen is essential. This study compares TC-H chemotherapy with weekly P-H chemotherapy in low risk patients and will provide us with more information regarding cost-effectiveness, toxicity, quality of life, patient reported outcomes and clinical benefits of the two strategies.
Sites: London Health Sciences Centre The Ottawa Hospital
Tags: Early stage Breast Cancer
Publications: Clinical Trial results: A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer. Fernandes et al, 2023. PMID: 37623016